A survey of glioblastoma genomic amplifications and deletions

Shailaja K. Rao, Jennifer Edwards, Avadhut D. Joshi, I. Mei Siu, Gregory J Riggins

Research output: Contribution to journalArticle

Abstract

Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating genomic DNA damage that often includes gene amplifications and/or deletions. These copy number changes can be a critical step in brain tumor development. To evaluate glioblastoma genomic copy number changes, we determined the genome-wide copy number alterations in 31 GBMs. Illumina Bead Arrays were used to assay 22 GBMs and Digital Karyotyping was used on 8 GBM cell lines and one primary sample. The common amplifications we observed for all 31 samples was GLI/CDK4 (22.6%), MDM2 (12.9%) and PIK3C2B/MDM4 (12.9%). In the 22 GBM tumors, EGFR was amplified in 22.7% of surgical biopsies. The most common homozygously deleted region contained CDKN2A/CDKN2B (p15 and p16) occurring in 29% of cases. This data was compiled and compared to published array CGH studies of 456 cases of GBMs. Pooling our Illumina data with published studies yielded these average amplification rates: EGFR-35.7%, GLI/CDK4-13.4%, MDM2-9.2%, PIK3C2B/MDM4-7.7%, and PDGFRA-7.7%. The CDKN2A/CDKN2B locus was deleted in 46.4% of the combined cases. This study provides a larger assessment of amplifications and deletions in glioblastoma patient populations and shows that several different copy number technologies can produce similar results. The main pathways known to be involved in GBM tumor formation such as p53 control, growth signaling, and cell cycle control are all represented by amplifications or deletions of critical pathway genes. This information is potentially important for formulating targeted therapy in glioblastoma and for planning genomic studies.

Original languageEnglish (US)
Pages (from-to)169-179
Number of pages11
JournalJournal of Neuro-Oncology
Volume96
Issue number2
DOIs
StatePublished - Jan 2010

Fingerprint

Glioblastoma
Brain Neoplasms
Karyotyping
Critical Pathways
Gene Amplification
Gene Deletion
Cell Cycle Checkpoints
Surveys and Questionnaires
DNA Damage
Neoplasms
Genome
Technology
Biopsy
Cell Line
Growth
Population
Genes

Keywords

  • Copy number alterations
  • Digital karyotyping
  • Genomic amplifications
  • Glioblastoma multiforme
  • Homozygous deletions
  • Oncogenomics
  • SNP array
  • Whole genome scans

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

A survey of glioblastoma genomic amplifications and deletions. / Rao, Shailaja K.; Edwards, Jennifer; Joshi, Avadhut D.; Siu, I. Mei; Riggins, Gregory J.

In: Journal of Neuro-Oncology, Vol. 96, No. 2, 01.2010, p. 169-179.

Research output: Contribution to journalArticle

Rao, Shailaja K. ; Edwards, Jennifer ; Joshi, Avadhut D. ; Siu, I. Mei ; Riggins, Gregory J. / A survey of glioblastoma genomic amplifications and deletions. In: Journal of Neuro-Oncology. 2010 ; Vol. 96, No. 2. pp. 169-179.
@article{c0155d83391f45cb89b097d6da379faf,
title = "A survey of glioblastoma genomic amplifications and deletions",
abstract = "Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating genomic DNA damage that often includes gene amplifications and/or deletions. These copy number changes can be a critical step in brain tumor development. To evaluate glioblastoma genomic copy number changes, we determined the genome-wide copy number alterations in 31 GBMs. Illumina Bead Arrays were used to assay 22 GBMs and Digital Karyotyping was used on 8 GBM cell lines and one primary sample. The common amplifications we observed for all 31 samples was GLI/CDK4 (22.6{\%}), MDM2 (12.9{\%}) and PIK3C2B/MDM4 (12.9{\%}). In the 22 GBM tumors, EGFR was amplified in 22.7{\%} of surgical biopsies. The most common homozygously deleted region contained CDKN2A/CDKN2B (p15 and p16) occurring in 29{\%} of cases. This data was compiled and compared to published array CGH studies of 456 cases of GBMs. Pooling our Illumina data with published studies yielded these average amplification rates: EGFR-35.7{\%}, GLI/CDK4-13.4{\%}, MDM2-9.2{\%}, PIK3C2B/MDM4-7.7{\%}, and PDGFRA-7.7{\%}. The CDKN2A/CDKN2B locus was deleted in 46.4{\%} of the combined cases. This study provides a larger assessment of amplifications and deletions in glioblastoma patient populations and shows that several different copy number technologies can produce similar results. The main pathways known to be involved in GBM tumor formation such as p53 control, growth signaling, and cell cycle control are all represented by amplifications or deletions of critical pathway genes. This information is potentially important for formulating targeted therapy in glioblastoma and for planning genomic studies.",
keywords = "Copy number alterations, Digital karyotyping, Genomic amplifications, Glioblastoma multiforme, Homozygous deletions, Oncogenomics, SNP array, Whole genome scans",
author = "Rao, {Shailaja K.} and Jennifer Edwards and Joshi, {Avadhut D.} and Siu, {I. Mei} and Riggins, {Gregory J}",
year = "2010",
month = "1",
doi = "10.1007/s11060-009-9959-4",
language = "English (US)",
volume = "96",
pages = "169--179",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A survey of glioblastoma genomic amplifications and deletions

AU - Rao, Shailaja K.

AU - Edwards, Jennifer

AU - Joshi, Avadhut D.

AU - Siu, I. Mei

AU - Riggins, Gregory J

PY - 2010/1

Y1 - 2010/1

N2 - Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating genomic DNA damage that often includes gene amplifications and/or deletions. These copy number changes can be a critical step in brain tumor development. To evaluate glioblastoma genomic copy number changes, we determined the genome-wide copy number alterations in 31 GBMs. Illumina Bead Arrays were used to assay 22 GBMs and Digital Karyotyping was used on 8 GBM cell lines and one primary sample. The common amplifications we observed for all 31 samples was GLI/CDK4 (22.6%), MDM2 (12.9%) and PIK3C2B/MDM4 (12.9%). In the 22 GBM tumors, EGFR was amplified in 22.7% of surgical biopsies. The most common homozygously deleted region contained CDKN2A/CDKN2B (p15 and p16) occurring in 29% of cases. This data was compiled and compared to published array CGH studies of 456 cases of GBMs. Pooling our Illumina data with published studies yielded these average amplification rates: EGFR-35.7%, GLI/CDK4-13.4%, MDM2-9.2%, PIK3C2B/MDM4-7.7%, and PDGFRA-7.7%. The CDKN2A/CDKN2B locus was deleted in 46.4% of the combined cases. This study provides a larger assessment of amplifications and deletions in glioblastoma patient populations and shows that several different copy number technologies can produce similar results. The main pathways known to be involved in GBM tumor formation such as p53 control, growth signaling, and cell cycle control are all represented by amplifications or deletions of critical pathway genes. This information is potentially important for formulating targeted therapy in glioblastoma and for planning genomic studies.

AB - Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating genomic DNA damage that often includes gene amplifications and/or deletions. These copy number changes can be a critical step in brain tumor development. To evaluate glioblastoma genomic copy number changes, we determined the genome-wide copy number alterations in 31 GBMs. Illumina Bead Arrays were used to assay 22 GBMs and Digital Karyotyping was used on 8 GBM cell lines and one primary sample. The common amplifications we observed for all 31 samples was GLI/CDK4 (22.6%), MDM2 (12.9%) and PIK3C2B/MDM4 (12.9%). In the 22 GBM tumors, EGFR was amplified in 22.7% of surgical biopsies. The most common homozygously deleted region contained CDKN2A/CDKN2B (p15 and p16) occurring in 29% of cases. This data was compiled and compared to published array CGH studies of 456 cases of GBMs. Pooling our Illumina data with published studies yielded these average amplification rates: EGFR-35.7%, GLI/CDK4-13.4%, MDM2-9.2%, PIK3C2B/MDM4-7.7%, and PDGFRA-7.7%. The CDKN2A/CDKN2B locus was deleted in 46.4% of the combined cases. This study provides a larger assessment of amplifications and deletions in glioblastoma patient populations and shows that several different copy number technologies can produce similar results. The main pathways known to be involved in GBM tumor formation such as p53 control, growth signaling, and cell cycle control are all represented by amplifications or deletions of critical pathway genes. This information is potentially important for formulating targeted therapy in glioblastoma and for planning genomic studies.

KW - Copy number alterations

KW - Digital karyotyping

KW - Genomic amplifications

KW - Glioblastoma multiforme

KW - Homozygous deletions

KW - Oncogenomics

KW - SNP array

KW - Whole genome scans

UR - http://www.scopus.com/inward/record.url?scp=75049085593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75049085593&partnerID=8YFLogxK

U2 - 10.1007/s11060-009-9959-4

DO - 10.1007/s11060-009-9959-4

M3 - Article

VL - 96

SP - 169

EP - 179

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -